Patents by Inventor Dongxiao Lan

Dongxiao Lan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12291495
    Abstract: The present invention refers to a process for preparing a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein R is (C3-C10)alkyl, or ?-trifluoro(C3-C10)alkyl; R1 and R2 are, independently, hydrogen, hydroxy, (C1-C8) alkoxy, (C1-C8) alkylthio, halo, trifluoromethyl or 2,2,2-trifluoroethyl; or one of R1 and R2 is in ortho position to the R—O— group and, taken together with the same R—O—, represents a Formula (A) group where R0 is (C2-C9)alkyl; R3 and R4 are, independently, hydrogen, (C1-C4)alkyl; or R4 is hydrogen and R5 is a group selected from —CH2—OH, —CH2—O—(C1-C6)alkyl, —CH(CH3)—OH, —(CH2)2—S—CH3, benzyl and 4-hydroxybenzyl; or R4 and R5, taken together with the adjacent carbon atom, form a (C3-C6)cycloalkyl residue; R5 and R6 are independently hydrogen or (C1-C6)alkyl; or taken together with the adjacent nitrogen atom form a 5-6 membered monocyclic saturated heterocycle, optionally containing one additional heteroatom chosen among —O—, —S— and —NR7— where R7 is hydrogen or (C1-C
    Type: Grant
    Filed: April 14, 2020
    Date of Patent: May 6, 2025
    Assignee: Newron Pharmaceuticals S.p.A.
    Inventors: William Leong, Dongxiao Lan, Weifang Zhang, Xiang Fang, Sizhong Wu
  • Publication number: 20220185766
    Abstract: The present invention refers to a process for preparing a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein R is (C3-C10)alkyl, or ?-trifluoro(C3-C10)alkyl; R1 and R2 are, independently, hydrogen, hydroxy, (C1-C8) alkoxy, (C1-C8) alkylthio, halo, trifluoromethyl or 2,2,2-trifluoroethyl; or one of R1 and R2 is in ortho position to the R—O— group and, taken together with the same R—O—, represents a Formula (A) group where R0 is (C2-C9)alkyl; R3 and R4 are, independently, hydrogen, (C1-C4)alkyl; or R4 is hydrogen and R5 is a group selected from —CH2—OH, —CH2—O—(C1-C6)alkyl, —CH(CH3)—OH, —(CH2)2—S—CH3, benzyl and 4-hydroxybenzyl; or R4 and R5, taken together with the adjacent carbon atom, form a (C3-C6)cycloalkyl residue; R5 and R6 are independently hydrogen or (C1-C6)alkyl; or taken together with the adjacent nitrogen atom form a 5-6 membered monocyclic saturated heterocycle, optionally containing one additional heteroatom chosen among —O—, —S— and —NR7— where R7 is hydrogen or (C1-C
    Type: Application
    Filed: April 14, 2020
    Publication date: June 16, 2022
    Applicant: Newron Pharmaceuticals S.p.A.
    Inventors: William Leong, Dongxiao Lan, Weifang Zhang, Xiang Fang, Sizhong Wu